Asia Oceania Journal of Nuclear Medicine and Biology

Asia Oceania Journal of Nuclear Medicine and Biology

Brain metastasis from differentiated thyroid carcinoma responding to radioiodine therapy

Document Type : Case report

Authors
Leo Hashimoto 1, 2, 3
Shiro Watanabe 1, 3, 4
Mungunkhuyag Majigsuren 3, 5
Kenji Hirata 1, 3, 4, 6
Junki Takenaka 1, 3
Rina Kimura 2, 3
Hiroshi Ishii 1, 3
Kohsuke Kudo 2, 3, 4, 6
1 Department of Nuclear Medicine, Hokkaido University Hospital, Sapporo, Japan
2 Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, Japan
3 Department of Diagnostic Imaging, Faculty of Medicine, Hokkaido University, Sapporo, Japan
4 Global Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, Sapporo, Japan
5 Department of Radiology, Diagnostic Imaging Center, Second State Central Hospital, Ulaanbaatar, Mongolia
6 Division of Medical AI Education and Research, Faculty of Medicine, Hokkaido University, Sapporo, Japan
10.22038/aojnmb.2025.86276.1618
Abstract
Brain metastasis (BM) occurs only in about 1% of differentiated thyroid carcinoma (DTC) cases. Although DTC generally has a good prognosis, once BM develops, the mortality rate significantly increases up to 78%. BM is usually treated by surgical resection or external radiotherapy, whereas radioactive iodine therapy (RAIT) using I-131 is much less often chosen because BM often shows poor uptake of I-131. In addition, even in case I-131 accumulates in the BM, RAIT could cause adverse effects such as brain hemorrhage and cerebral edema.
We present a case of BM from DTC that showed response to I-131 therapy with no severe adverse effects. The brain lesion was very small and asymptomatic, and was only found after a post-therapy I-131 scintigraphy. There are a few case reports where BM was cured by RAIT with little to no side effects. We theorize that BM that is small in size, asymptomatic and show I-131 accumulation could be successfully treated with RAIT.
Keywords
Thyroid cancer
Radioiodine
Brain metastasis
Subjects
  1. Gomes-Lima CJ, Wu D, Rao SN, Punukollu S, Hritani R, Zeymo A, et al. Brain metastases from differentiated thyroid carcinoma: Prevalence, current therapies, and outcomes. Journal of the Endocrine Society. 2019; 3(2): 359-71.
  2. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism. 1997; 82(11): 3637-42.
  3. Misaki T, Iwata M, Kasagi K, Konishi J. Brain metastasis from differentiated thyroid cancer in patients treated with radioiodine for bone and lung lesions. Ann Nucl Med. 2000; 14(2): 111-4.
  4. Ha LN, Khanh LQ, Hanh NTM, Seo HJ, Son MH. Screening and treatment of brain metastasis from papillary thyroid carcinoma: a case series. Thyroid Res. 2023; 16(1): 1-10.
  5. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016; 26(1): 1-133.
  6. Scharrenbach V, Wunderlich A, Hassan I, Lingelbach S, et al. Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: Evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors. The Journal of Clinical Endocrinology & Metabolism. 2004; 89(12): 6139-45.
  7. Tumino D, Frasca F, Newbold K. Updates on the management of advanced, metastatic, and radioiodine refractory differentiated thyroid cancer. Front Endocrinol (Lausanne). 2017; 8: 312.
  8. Vrachimis A, Schmid KW, Jürgens H, Schober O, Weckesser M, Riemann B. Cerebral metastases from thyroid carcinoma. Dtsch Arztebl Int. 2013; 110(50): 861-6.
  9. Santhosh S, Bhattacharya A, Verma RK, Lal A, Mittal BR. A rare case of asymptomatic radioiodine-avid renal and brain metastases 20 years after hemi-thyroidectomy for adenomatous goiter. Indian J Nucl Med. 2016; 31(1): 42-4.
  10. Sabra MM, Dominguez JM, Grewal RK, Larson SM, Ghossein RA, Tuttle RM, et al. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. The Journal of Clinical Endocrinology & Metabolism. 2013; 98(5): E829-36.
Asia Oceania Journal of Nuclear Medicine and Biology
Volume 13, Issue 2
July 2025
Pages 208-212